Gyre Therapeutics Inc GYRE

$4.55 -1.86 (-29.02%)

Valuation

Market cap
714,779,000
Revenue TTM
$116,590,000
Net income TTM
$5,030,000
PE ratio
0.00
Forward PE
—
Profit margin
4.31%
Debt to equity
0.00

Trading

Volume
394,000
Avg volume
148,414
Day's range
$4.51 – $6.30
Shares out
111,510,000
Stochastic %K
2%
Beta
1.89
Analysts
Strong Sell
Price target
$18.67

Price

Company profile

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351...

Show more

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Industry
Biotechnology
Sector
Healthcare
Phone
858-284-0115
Website
https://www.gyretx.com
Address
12730 High Bluff Drive, Suite 250, San Diego, United States

Latest news

Stocktwits

Arcides Oct 30, 4:34 PM
$GYRE some bios are being totally broken today.
0 replies
ajmrtxl Oct 22, 6:00 PM
$GYRE 's latest squeeze play
1 replies
Channelchek Aug 10, 4:25 PM
Noble Capital Markets Research Report: Gyre Therapeutics, Inc ($GYRE) – Gyre Reports 2Q26 Results Completes The Transformative Cullgen Acquisition The Cullgen Acquisition Highlights 2Q26. Gyre reported a 2Q26 loss of $14.3 million, or $(0.12) per share. Revenues of $29.1 million compared with $22.5 million in 1Q26, consistent with our estimates. We have expected a transition year between Etuary market maturity and the expected hydronidone launch, supplemented by the Cullgen acquisition. Read full report here: https://www.channelchek.com/news-channel/gyre-therapeutics-inc-gyre-gyre-reports-2q26-results-completes-the-transformative-cullgen-acquisition
0 replies
StocktwitsEarnings Aug 7, 12:09 PM
$GYRE Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 • Reported revenue of $29.11M up 8.72% YoY • Gyre Therapeutics, Inc. affirmed its full year 2026 revenue guidance of $100.5 million to $111.0 million, reflecting the company's outlook for its commercial-stage biopharmaceutical product portfolio and development initiatives.
0 replies
kule04 Aug 3, 5:26 PM
$GYRE Damn, noone writes here... Close to it's 52 week low, far from it's high and with genuine catalysts to get back up there... Cash is beautiful
0 replies
MilsLearning May 22, 7:56 PM
$GYRE 🩳🔥🖕
0 replies
stockwuzet May 14, 9:45 PM
$GYRE https://www.sec.gov/Archives/edgar/data/1124105/000114036126021360/ef20073544_8k.htm https://www.sec.gov/Archives/edgar/data/1124105/000114036126021360/ef20073544_ex99-1.htm
0 replies
stockwuzet May 12, 9:30 PM
$GYRE https://finviz.com/news/353599/gyre-therapeutics-announces-nmpa-acceptance-of-new-drug-application-for-f351-hydronidone-for-chb-induced-liver-fibrosis-treatment
0 replies